The recent 2021 WHO classification defined a unique tumor family based on these molecular alterations, which encompasses gliomas ranging from low to high grade and is distinct from IDH wild‐type glioblastomas at the molecular level.3 The gene discussed is IDH1; the disease is central nervous system cancer.